Paradigm has reported a strong pain and function signal for iPPS outside the US, including a 1.105-point advantage over placebo at Day 112. The result does not revive the halted Phase 3 trial, with the company under administration and a potential funding proposal still unreceived.
- ROW iPPS patients recorded 1.105 points more pain relief than placebo at Day 112
- Statistically significant improvements also emerged in function, WOMAC pain and PGIC
- The post hoc analysis covered 16 sites across Australia, Hong Kong and Moldova
- The overall futility outcome remains unchanged and PARA_OA_012 will not proceed
- Administrators are awaiting a possible funded proposal from the former Board
ROW analysis reveals a sizeable iPPS treatment signal
Paradigm Biopharmaceuticals Limited (Administrators Appointed) (ASX:PAR) has found a statistically significant pain benefit for its iPPS osteoarthritis treatment outside the United States, but the result arrives too late to restart the Phase 3 trial. Across 16 sites in Australia, Hong Kong and Moldova, patients receiving iPPS recorded 1.105 points more pain reduction than those on placebo at Day 112, on a 0 to 10 scale. The reported p-value was 0.0007, with an effect-size magnitude of 0.708.
The regional result emerged from an internal, post hoc analysis of observed data extracted on 30 September. It covered 114 randomised participants, with Day 112 pain assessments available for 95 of them. That is a materially larger assessed population than the 41-patient twice-weekly comparison used in the earlier PARA_OA_008 study, although the analysis remains regional and was not the trial's original overall outcome.
Pain relief was accompanied by better function and patient-reported improvement
The signal was not confined to daily pain. At Day 112, the ROW iPPS group also outperformed placebo on WOMAC physical function, WOMAC pain and the Patient Global Impression of Change. The reported differences were 1.017 points for function, 0.821 points for WOMAC pain and 1.077 points on the patient-improvement scale, with p-values of 0.0026, 0.0147 and 0.0032 respectively.
Every plotted ROW timepoint from Day 25 through Day 140 favoured iPPS for weekly average daily pain, including the primary Day 112 assessment. By Day 168, however, only 25 observed assessments remained and the treatment difference had narrowed with a confidence interval crossing zero. That later estimate is therefore less precise than the Day 112 result.
US data and missing assessments remain the central complication
The findings contrast sharply with the US dataset, where the Day 112 observed-data results did not show an iPPS advantage across pain, function, WOMAC pain or PGIC. Of the 97 participants missing Day 112 weekly pain data at the interim analysis, 91 were from the US. The company’s review identified missed doses, specialist laboratory delays, diary completion and other operational factors as issues requiring further assessment.
That review matters because the overall interim analysis met its futility criteria, and the trial will not proceed. The regional findings do not overturn that decision. Paradigm also cautions that missing-data imputation alone cannot be assumed to explain the difference between the US and ROW results, while the joint administrators say they have not independently verified the analysis.
Administration leaves any iPPS rescue dependent on funding
The update lands shortly after entry into voluntary administration, with Paradigm’s securities still suspended from trading. The administrators have been notified that the former Board is preparing a proposal intended to preserve the iPPS program and establish a funded development path, potentially involving clinical development, regulatory engagement, funding and restructuring.
No proposal had been received or assessed as at the announcement. Any continuation would depend on the proposal being finalised, funding being secured, applicable approvals and the administration process. The immediate question is therefore not whether the ROW data contains a promising signal; it is whether that signal can be converted into a credible, independently scrutinised and financeable development plan while the overall Phase 3 result remains adverse.
Bottom Line?
The ROW data gives iPPS a potentially valuable efficacy signal, but it has no practical development value unless the administrators receive and approve a funded plan that resolves the trial’s regional and operational uncertainties.
Questions in the middle?
- Can the former Board deliver a funded proposal that creditors and administrators are prepared to support?
- How much of the US and ROW divergence is explained by dosing interruptions, missing data and site operations?
- Will regulators regard the post hoc ROW analysis as sufficient to justify a new or redesigned clinical program?